The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The potential of combining chemotherapy with allogeneic CAR-NK cells in AML: a Phase I trial
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of combining chemotherapy with allogeneic CAR-NK cells in acute myeloid leukemia (AML). Dr Ravandi highlights that the results of the Phase I SENTI-202-101 trial (NCT06325748) will be presented at the meeting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Cellular therapy and immunotherapy has been very effective in lymphoid malignancies. We are still lagging in the myeloid arena in terms of having effective immune-based strategies, except for allogeneic stem cell transplant, of course. This study is looking at a combination of chemotherapy followed by allogeneic CAR-NK cells modified to target both CD33 and FLT3, which is expressed highly on AML blasts...
Cellular therapy and immunotherapy has been very effective in lymphoid malignancies. We are still lagging in the myeloid arena in terms of having effective immune-based strategies, except for allogeneic stem cell transplant, of course. This study is looking at a combination of chemotherapy followed by allogeneic CAR-NK cells modified to target both CD33 and FLT3, which is expressed highly on AML blasts. There is a NOTCH gate that prevents the NK cells from attacking normal hematopoietic stem cells because the main side effect of cellular therapies in AML has been prolonged myelosuppression through the effect on normal hematopoietic cells. So we hope that with this strategy we can induce some immune-based anti-leukemic activity without causing significant toxicity and the study is ongoing and the results of the early cohort of patients are being presented at this ASH.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
